Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Reports Findings of Commissioned Study Showing a Majority of Affected Americans Approve of Psychedelics as an Alternative Treatment for Select Mental Conditions
The Harris Poll conducted a survey on behalf of Delic Holdings, polling 2,037 adults ages 18 and older, 953 of whom suffer from anxiety/depression/PTSD The survey revealed that 65% of Americans living with anxiety/depression/PTSD believe that psychedelic medicine should be available to patients with treatment-resistant conditions 66%, 62%, and 56% are open to pursuing ketamine, psilocybin, and MDMA, respectively, to treat anxiety/depression/PTSD if these psychedelic drugs were each proven more effective than prescription medication with fewer side effects Though the U.S. government has not yet federally recognized a medical use for most psychedelic drugs, research by renowned universities and companies…